Solventum Corporation (SOLV)
NYSE:SOLV
SOLV Stock Chart & Stats
$65.69
-$0.47(-0.68%)
At close: 4:00 PM EST
$65.69
-$0.47(-0.68%)
Day’s Range― - ―
52-Week Range$60.70 - $88.20
Previous CloseN/A
Volume531.14K
Average Volume (3M)1.29M
Market Cap
$11.40B
Enterprise Value$15.55B
Total Cash (Recent Filing)$878.00M
Total Debt (Recent Filing)$5.04B
Price to Earnings (P/E)8.9
Beta0.66
Next Earnings
May 07, 2026EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding173,493,010
10 Day Avg. Volume1,514,079
30 Day Avg. Volume1,291,888
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.73
Price to Sales (P/S)1.66
P/FCF Ratio-1.38K
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda5.53
Forecast
1Y Price Target
$91.50Price Target Upside39.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)6.48
Revenue Forecast (FY)$8.16B
Bulls Say, Bears Say
Bulls Say
Proprietary AI Coding SolutionInvestment in a proprietary hybrid autonomous coding solution that combines generative models, natural language processing and rule-based expertise positions Solventum to automate routine coding while preserving accuracy for complex cases, reinforcing its competitive moat in revenue cycle management.
Revenue OutperformanceSolventum reported revenue and adjusted earnings above analyst expectations, led by dental and medical surgical segment strength that may prompt upward revisions to growth forecasts.
Transformation-driven Cost SavingsProgress on the transformation program, including ERP deployments and distribution center consolidation, is expected to deliver meaningful cost savings that support margin improvement and greater operational efficiency.
Bears Say
Investor Uncertainty On AI And ExecutionInvestor concern that artificial intelligence could disrupt the health information systems business, coupled with a Neutral analyst rating on the turnaround, creates an overhang on confidence and may limit valuation multiple expansion.
Margin ShortfallAdjusted gross margins and operating margins missed expectations due to one-time margin dynamics, exerting near-term pressure on profitability until identified cost improvements materialize.
Tariff-related Cost PressuresTariff-related headwinds are likely to increase operating costs and pressure earnings, potentially compressing margins and challenging pricing flexibility.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $60.70 and its highest was $88.20 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $11.40B.
When is Solventum Corporation’s upcoming earnings report date?
Solventum Corporation’s upcoming earnings report date is May 07, 2026 which is in 43 days.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on Feb 26, 2026. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $1.495 by $0.075.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate is 1.35.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 173,493,010 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $1.57 in its last earnings report, beating expectations of $1.495. Following the earnings report the stock price went down -3.561%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in SOLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solventum Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$91.50 (39.29% Upside)
$91.50 (39.29% Upside)
Blogger Sentiment
Bullish
SOLV Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.19%
12-Months-Change
Fundamentals
Return on Equity
36.74%
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Company Description
Solventum Corporation
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
SOLV Company Deck
SOLV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive operational progression: the company delivered organic growth, a full-year EPS beat, meaningful restructuring savings, strategic portfolio moves (Acera acquisition and P&F divestiture) and a $1B repurchase program while making visible progress on separation from 3M. However, near-term pressures remain material — Q4 gross margin headwinds from ERP/DC cutovers and logistics, free cash flow and separation/divestiture costs, SKU rationalization impacts, tariff exposure and an elevated net debt position. Management provided credible plans (Transform for the Future, additional ERP/system independence, supply-chain optimization) and guidance showing modest margin expansion and mid-single-digit organic growth targets for 2026, with the bulk of larger program benefits expected in 2027+. Overall, positives (growth acceleration, EPS beat, cost savings, strategic M&A and buyback) outweigh the near-term operational and separation-related headwinds, but execution risk remains important over the next 12–18 months.View all SOLV earnings summariesSOLV Stock 12 Month Forecast
Average Price Target
$91.50
▲(39.29% Upside)
Technical Analysis
DaVita
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―
Ownership Overview
14.91% Insiders
19.73% Mutual Funds
29.20% Other Institutional Investors
14.88% Public Companies and
Individual Investors